Table 2.
Most frequent AIDS-related conditions at baseline, by group.
| Study group | ||||||||
|---|---|---|---|---|---|---|---|---|
| Dolutegravir (n = 92) | Efavirenz (n = 92) | |||||||
| n | % | 95%CI | n | % | 95%CI | |||
| Esophageal candidiasis | 28 | 30.8% | 22.0% | −40.7% | 25 | 27.5% | 19.1% | −37.2% |
| Neurotoxoplasmosis | 30 | 32.6% | 23.7% | −42.6% | 12 | 13.0% | 7.3% | −21.0% |
| P. jirovecii pneumonia | 21 | 22.8% | 15.2% | −32.2% | 14 | 15.2% | 9.0% | −23.6% |
| Bacterial pneumonia (recurrent) | 15 | 16.3% | 9.8% | −24.8% | 14 | 15.2% | 9.0% | −23.6% |
| Tuberculosis | 14 | 15.2% | 9.0% | −23.6% | 16 | 17.4% | 10.7% | −26.1% |
| Chronic diarrhea | 10 | 10.9% | 5.7% | −18.4% | 15 | 16.3% | 9.8% | −24.8% |
| Wasting syndrome | 9 | 9.8% | 5.0% | −17.1% | 9 | 9.8% | 5.0% | −17.1% |
| Neurocryptococcosis | 7 | 7.6% | 3.5% | −14.4% | 3 | 3.3% | 0.9% | −8.4% |
| Cytomegalovirus infection | 5 | 5.4% | 2.1% | −11.5% | 1 | 1.1% | 0.1% | −5.0% |
| Disseminated histoplasmosis | 5 | 5.4% | 2.1% | −11.5% | 3 | 3.3% | 0.9% | −8.4% |
| Malignancies | 4 | 4.3% | 1.5% | −10.0% | 2 | 2.2% | 0.5% | −6.8% |
| Disseminated herpes Zoster | 4 | 4.3% | 1.5% | −10.0% | 0 | 0.0% | ||